Table 2 Physical and clinical characteristics of the participants.

Sex (male/female)

29/34

18/25

0.673

Age (years)

68.87 ± 7.01

65.60 ± 5.74

0.058

Height (cm)

160.72 ± 7.76

160.48 ± 8.38

0.878

Body mass (kg)

62.79 ± 10.38

63.17 ± 10.35

0.853

BMI (kg/m²)

24.25 ± 3.26

24.40 ± 2.58

0.797

LHGS (kg)

25.62 ± 7.31

28.80 ± 2.58

0.039^a

RHGS (kg)

26.72 ± 7.55

30.37 ± 9.51

0.063

FTSTS (s)

8.70 ± 3.59

7.07 ± 2.14

0.002^b

6MWT (m)

414.31 ± 90.38

493.90 ± 52.34

< 0.001^b

K-MMSE (scores)

28.08 ± 1.90

27.30 ± 1.83

0.012^b

H&Y scale (stages 1 and 2)

24/39

–

–

UPDRS total (scores)

47.86 ± 20.27

–

–

UPDRS part Ⅲ (scores)

25.51 ± 14.18

–

–

L-Dopa equivalent dose (mg/day)

510.09 ± 242.47

–

–

Treatment duration (years)

4.05 ± 3.27

–

–

Symptom duration (years)

4.97 ± 3.37

–

–

More affected side (Left/Right/Bilateral) (%)

31/23/9 (49.2%/36.5%/14.3%)

–

–